DOCUMENT
01_The impact of HIV-associated CCM on health.pdf (3.5 MB)
DOCUMENT
02_The pathophysiology of HIV-associated CCM.pdf (1.58 MB)
DOCUMENT
03_Signs and symptoms of HIV-associated CCM.pdf (1.24 MB)
DOCUMENT
04_Diagnosing HIV-associated CCM.pdf (2.18 MB)
DOCUMENT
05_Treatment of HIV-associated CCM.pdf (2.79 MB)
DOCUMENT
06_Managing HIV-associated CCM.pdf (3.53 MB)
DOCUMENT
07_Further management of HIV-associated CCM.pdf (3.8 MB)
DOCUMENT
Poster 01_HIV-associated Cryptococcal Meningitis.pdf (1.06 MB)
DOCUMENT
Poster 02_CrAg LFA RDT.pdf (476.4 kB)
DOCUMENT
Poster 03_CryptoPS LFA RDT.pdf (502.61 kB)
DOCUMENT
Poster 04_5-FC and Fluconazole Administration.pdf (436.53 kB)
DOCUMENT
Poster 05_Safe AmB Administration.pdf (579.23 kB)
DOCUMENT
DREAMM Education programme overview.pdf (433.65 kB)
DOCUMENT
Workshop 01_Cryptococcal Antigen (CrAg) Lateral Flow Assay (LFA) Test.pdf (1.02 MB)
DOCUMENT
Workshop 02_Safe Administration of Flucytosine and Fluconazole administration_treating CCM.pdf (890.95 kB)
DOCUMENT
Workshop 03_Safe Administration of Amphotericin B_treating CCM.pdf (1.03 MB)
1/0
HIV–associated Cryptococcal Meningitis
Version 4 2023-10-03, 13:43
Version 3 2023-10-03, 13:25
Version 2 2018-12-03, 09:16
Version 1 2018-11-30, 15:32
educational resource
posted on 2023-10-03, 13:43 authored by Muirgen StackMuirgen Stack, Timothée Boyer-chammard, Sayoki G. Mfinanga, Sokoine L. Kivuyo, Cecilia Kanyama, Saulos Nyirenda, Charles Kouanfack, Lauriane Fomete Nome, Aude Sturny Leclere, Olivier Lortholary, Tom Harrison, Anne-Marie Reid, Angela LoyseThe DREAMM education programme and all related training materials are intended for health care workers (HCWs) based/working in low and middle income countries (LMICs) across Africa.
The DREAMM education programme aims to increase the knowledge of HCWs to effectively diagnose and treat symptomatic people living with HIV (PLHIV) who present with symptoms and signs compatible with a diagnosis of meningo-encephalitis.
This module and supporting posters and workshops focus on HIV-associated cryptococcal meningitis, a leading cause of HIV-related meningo-encephalitis in many LMICs and is estimated to make up to 20% of HIV-related deaths in LMICs.
The cryptococcal meningitis training module consists of 7 sections (it is recommend to view sequentially):
- The impact of HIV-associated cryptococcal meningitis on health
- The pathophysiology of HIV-associated cryptococcal meningitis
- Signs and symptoms of HIV-associated cryptococcal meningitis
- Diagnosing HIV-associated cryptococcal meningitis
- Treatment of HIV-associated cryptococcal meningitis
- Managing HIV-associated cryptococcal meningitis: monitoring and complications
- Further management of cryptococcal meningitis: raised intracranial pressure, ART initiation and significant drug interactions
- The pathophysiology of HIV-associated cryptococcal meningitis
- Signs and symptoms of HIV-associated cryptococcal meningitis
- Diagnosing HIV-associated cryptococcal meningitis
- Treatment of HIV-associated cryptococcal meningitis
- Managing HIV-associated cryptococcal meningitis: monitoring and complications
- Further management of cryptococcal meningitis: raised intracranial pressure, ART initiation and significant drug interactions
There are three HIV-associated cryptococcal meningitis training workshops:
- Cryptococcal Antigen (CrAg) Lateral Flow Assay (LFA) Test – Diagnosing Cryptococcal Meningitis
- Safe Administration of Amphotericin B deoxycholate – Treating Cryptococcal Meningitis
- Safe Administration of Flucytosine and Fluconazole – Treating Cryptococcal Meningitis
The HIV-associated cryptococcal meningitis training posters are titled:
- Safe Administration of Amphotericin B deoxycholate – Treating Cryptococcal Meningitis
- Safe Administration of Flucytosine and Fluconazole – Treating Cryptococcal Meningitis
The HIV-associated cryptococcal meningitis training posters are titled:
- HIV-associated Cryptococcal Meningitis
- Safe Amphotericin Deoxycholate (AmB) Administration
- Flucytosine (5-FC) and Fluconazole Administration for HIV-related Cryptococcal Meningitis
- How to perform a cryptococcal Antigen Lateral Flow Assay (CrAg LFA): IMMY CrAg
- How to perform a cryptococcal Antigen Lateral Flow Assay (CrAg LFA): Biosynex CryptoPS
- Safe Amphotericin Deoxycholate (AmB) Administration
- Flucytosine (5-FC) and Fluconazole Administration for HIV-related Cryptococcal Meningitis
- How to perform a cryptococcal Antigen Lateral Flow Assay (CrAg LFA): IMMY CrAg
- How to perform a cryptococcal Antigen Lateral Flow Assay (CrAg LFA): Biosynex CryptoPS
Funding
European and developing countries clinical trials programme (EDCTP)
European Commission
Find out more...French Agency for Research on AIDS and Viral Hepatitis (co-funders and co-sponsors of Cameroon site)
History
Usage metrics
Categories
Keywords
AIDSCryptococcus neoformansglobal healthClinical trainingmeningitisHIV Antiretroviral TherapyCapacity Building in the field of Higher EducationFungal infectionsTanzaniaMalawiCameroonCNS infectionsRapid Diagnostic TestLMICsPLHIVHealthcare workersPublic Health DataEDCTPANRSInfectious DiseasesHealth CareMedicine, Nursing and Health Curriculum and Pedagogy
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC